912635-62-2 Usage
Chemical structure
The compound consists of a tetrahydropyrrole and pyrazole ring system with a carboxylic acid ethyl ester group.
Application in medicinal chemistry
It is often used as a building block for the synthesis of potential pharmaceutical compounds.
Versatility
Its unique structure and functional groups make it a versatile intermediate for the creation of diverse bioactive molecules.
Suitability for modification
The compound has properties that make it suitable for further modification and biological testing.
Potential therapeutic applications
It can be used to study its potential therapeutic applications in various diseases.
Diverse chemical reactivity
Its complex structure and functional groups offer potential for diverse chemical reactivity.
Applications in material science
The compound may have potential applications in material science and other chemical processes.
Check Digit Verification of cas no
The CAS Registry Mumber 912635-62-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,2,6,3 and 5 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 912635-62:
(8*9)+(7*1)+(6*2)+(5*6)+(4*3)+(3*5)+(2*6)+(1*2)=162
162 % 10 = 2
So 912635-62-2 is a valid CAS Registry Number.
912635-62-2Relevant academic research and scientific papers
As Aurora kinase inhibitor derivatives
-
, (2019/06/27)
The present invention relates to a substituted pyrazole derivative used for inhibiting Aurora kinase and represented by formula (I) or formula (Ia), or stereo isomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof, a medicinal composition containing the above compounds as active ingredients, and a use of the compounds and the medicinal composition in preparation of medicines for protecting, processing, treating or mitigating proliferative diseases of patients.
Tricyclic azole derivatives
-
Page/Page column 17, (2010/11/24)
The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing th
